Investor & media center

Corporate Overview

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies.

PYC believes its CPP technology provides safer, more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets.

PYC’s discovery and laboratory operations are located in Australia and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and business development operations.

Corporate Overview

ASX Announcements

Events

Upcoming Events Past Events

Upcoming Events

More events are coming soon

Past Events

Webcast: PYC Therapeutics Limited

01/14/2021 View Event

AGM 2020

11/06/2020 View Event

Turning RNA Research into Medicines Panel

02/17/2021 View Event

Select Area of Interest

Financial and Annual Reports Corporate Governance Charters Policies and Procedures

PYC Therapeutics Limited (“Company”) has adopted a Corporate Governance Plan which forms the basis of a comprehensive system of control and accountability for the administration of corporate governance.

The Board is committed to administering the policies and procedures with openness and integrity, pursuing the true spirit of corporate governance commensurate with the Company’s needs.

To the extent they are applicable to the Company, the Board has adopted the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations 3rd Edition (“Principles & Recommendations”).

A Corporate Governance Statement sets out details of the Company’s compliance with the Principles & Recommendations. Click here to read the ASX Corporate Governance Principles & Recommendations.

The Company is pleased to make the following information on its corporate governance practices available on this website.

Investor Relations and Media Contacts

Investors

Deborah Elson and Matthew DeYoung
Argot Partners
001.212.600.1902
deborah@argotpartners.com | matthew@argotpartners.com

Media

Leo Vartorella
Argot Partners
001.212.600.1902
leo@argotpartners.com

Discover more about our Pipeline

We are combining our proprietary CPP technology with world-leading expertise in PMO design to create a pipeline of highly precise, safe and effective combination drugs.

Our Pipeline

Investor & media center

Corporate Overview

ASX Announcements

2021

Lead Investigational Drug Demonstrates Key Improvement

Half Year Accounts and Appendix 4D

PYC Expands US Executive Leadership Team

Progress US Clinical Stage Company and Corporate Objectives

PYC to Participate in RNA Discussion – BIO CEO Conference

December 2020 Quarterly Report and Cashflow

ICR Conference Presentation

PYC to Present at ICR Westwicke Conference

2020

Letter to Shareholders from the US CEO

Appointment of Chief Executive Officer in the United States

Change in substantial holding – Change in substantial holding

Retail Entitlement Offer Share Issue and Appendix 2A

Completion of Retail Entitlement Offer

New Drug for Substantial Unmet Need Added to Pipeline

Technical Presentation – October 2020

Notice of Directors intention not to seek re election at AGM

Investor Call 15th Oct 2020 12pm AEDT 9am AWST

Cancellation of Unlisted Options

PYC’s Lead Drug Effective in Patient Derived Models Tested

Notice of Annual General Meeting:Proxy Form

Corporate Governance Statement and Appendix 4G

Annual Report to shareholders

Second Potential Blockbuster Drug Added to PYC’s Pipeline

Annual Financial Statements June 2020

Creation of Novel Gene Therapy Delivery Technology

Appendix 4E Preliminary Final Report

Appointment of world-renowned Chief Scientific Officer

Shareholder Update August 2020

Shareholder Update – Forward View 2020 Milestones

Investor Call – 8am AWST – Wednesday 12 August 2020

June 2020 Quarterly Activity Report and Cashflow

Successful Dose Response & Toxicity Studies in Lead Program

Appendix 2A

Appendix 3G

Investor Presentation

Change of Director’s Interest Notice x 2

Change in substantial holding

PYC Recruits High Profile Chief Medical Officer to US Ops

Appendix 3G

World Class Results – Lions Eye Institute News Release

March 2020 Quarterly Activities and Cash Flow Report

Efficacy and Toxicity Studies Presentation

Successful Toxicity Results Confirm Safety Advantage

Trading Halt

Investor Call 9.00am AWST Wed 1 April 2020

Becoming a substantial holder

Half Yearly Report and Accounts

Investor Presentation

Appendix 3G

Appendix 3G

NHMRC Grand for Identifying new Antisense Drugs

Visual Evidence of Lead Drugs Efficacy

Appendix 3G

Initial Director’s Interest Notice

CEO Appointment & Establishment of US Office

Investor Call 27 February 2020

Appendix 4C – Quarterly

Change of Share Registry

2019

Quarterly Shareholder Update

Drug Delivery Greater than 100% more Effective – Amended

Change in Director’s Notice x 2

Change in Substantial Holding_v2

Change in Substantial Holding

Drug Delivery Greater than 100%

2019 AGM Chairman’s Address

Change in Substantial Holding

2019 AGM Presentation

Completion of Retail Entitlement Offer

Conclusion of Genentech Antimicrobial Collaboration

PYC Increases Shareholding in Vision Pharma

Change in Substantial Holding

Change of Director’s Interest Notice

Change in Substantial Holding

Appendix 3B